Aldafermin, an engineered analog of FGF19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with non-alcoholic steatohepatitis (NASH).
Aldafermin, an engineered analog of FGF19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with non-alcoholic steatohepatitis (NASH).